【レポートの概要（一部）】
1. Report Overview
1.1 The Prostate Cancer Therapeutics Market Overview
1.2 Prostate Cancer Therapeutics Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. Introduction to Prostate Cancer
2.1 What is Cancer?
2.2 Phenotypic Characteristics of Cancer Cells
2.2.1 Uncontrollable Growth
2.2.2 Loss of Apoptosis Pathways
2.2.3 Lack Differentiation
2.2.4 Increased Angiogenesis
2.2.5 Potential for Metastasis
2.2.6 Genetic Instability
2.3 What Causes Cancer?
2.4 Worldwide Prevalence of Cancer: A Global Picture
2.5 What is Prostate Cancer?
2.6 Worldwide Prevalence of Prostate Cancer: Rapid Global Growth
2.7 Risk Factors for Prostate Cancer
2.8 How is Prostate Cancer Diagnosed?
2.8.1 PSA Testing
2.8.2 Digital Rectal Examination Testing
2.8.3 Prostate Cancer Screening: Beneficial or Costly?
2.8.4 Newly Approved Tests May Improve Diagnosis
2.8.4.1 Prostate Cancer Diagnostics in the Pipeline
2.9 Treatment Sequence for Prostate Cancer
2.9.1 Localised Prostate Cancer: Surgery/Radiation is Most Preferred
2.9.1.1 Brachytherapy
2.9.1.2 Radical Prostatectomy
2.9.1.3 External Beam Radiation Therapy
2.9.1.4 Cryotherapy
2.9.1.5 High-Intensity Focussed Ultrasound (HIFU)
2.9.2 Advanced Local or Metastatic Prostate Cancer: Androgen Deprivation Therapy
2.9.3 Non-Metastatic CRPC: Ketoconazole and Anti-Androgens
2.9.4 Metastatic CRPC: Expanding the Standard Taxotere Treatment Paradigm
2.9.5 First Line Chemotherapy: Docetaxel is a Standard Treatment
2.9.6 Post Docetaxel Therapy: Five FDA Approved Drugs
2.9.7 Second Line Chemotherapy: Jevtana Approved in 2010
3. The Prostate Cancer Therapeutics Market 2014-2024
3.1 The Global Prostate Cancer Therapeutics Market, 2013
3.2 The Global Prostate Cancer Therapeutics Market Forecast, 2014-2024
3.3 The Global Prostate Cancer Therapeutics Market: Drivers and Restraints, 2014-2024
4. The Prostate Cancer Drugs Market 2014-2024
4.1 The Prostate Cancer Drugs Market: Increasing Choice of Drugs will Mean Higher Competition
4.2 The Prostate Cancer Drugs Market, 2013
4.3 Leading Prostate Cancer Drugs: Market Forecast, 2014-2024
4.3.1 The Market Shares of Leading Prostate Cancer Drugs, 2014-2024
4.4 First Generation Chemotherapies
4.4.1 Taxotere (Sanofi)
4.4.1.1 Taxotere Sales, 2013
4.4.1.2 Taxotere Sales Forecast, 2014-2024
4.5 Second Generation Chemotherapies
4.5.1 Jevtana (Sanofi)
4.5.1.1 Jevtana Sales, 2013
4.5.1.2 Jevtana Sales Forecast, 2014-2024
4.6 First Generation Hormones
4.6.1 Casodex (AstraZeneca)
4.6.1.1 Casodex Sales, 2013
4.6.1.2 Casodex Sales Forecast, 2014-2024
4.6.2 Lupron (AbbVie)
4.6.2.1 Lupron Sales, 2013
4.6.2.2 Lupron Sales Forecast, 2014-2024
4.6.3 Zoladex (AstraZeneca)
4.6.3.1 Zoladex Sales, 2013
4.6.3.2 Zoladex Sales Forecast, 2014-2024
4.7 Second Generation Hormones
4.7.1 Zytiga (Johnson & Johnson)
4.7.1.1 Zytiga Sales, 2013
4.7.1.2 Zytiga Sales Forecast, 2014-2024
4.7.2 Xtandi (Medivation/ Astellas Pharma)
4.7.2.1 Xtandi Sales, 2013
4.7.2.2 Xtandi Sales Forecast, 2014-2024
4.8 Immunotherapies
4.8.1 Provenge (Dendreon Corporation)
4.8.1.1 Provenge Sales, 2013
4.8.1.2 Provenge Sales Forecasts, 2014-2024
4.9 Radiopharmaceuticals
4.9.1 Xofigo (Bayer)
4.9.1.1 Xofigo Sales, 2013
4.9.1.2 Xofigo Sales Forecast, 2014-2024
4.10 Other Drugs
4.11 Prostate Cancer Drugs Pipeline, 2014
4.11.1 Phase III Development
4.11.1.1 DCVax-Prostate (NorthWest Biotherapeutics)
4.11.1.2 Tookad Soluble (Steba Biotech)
4.11.1.3 ProstAtak (Advantagene)
4.11.1.4 Tasquinimod (Active biotech AB/Ipsen)
4.11.1.5 Custirsen (Oncogenex/ Teva)
4.11.1.6 Cabozantinib (Exelixis)
4.11.1.7 Prostvac (Bavarian Nordic)
4.11.2 Failed Phase III Drugs
4.11.2.1 Custirsen (OncoGenex)
4.11.2.2 Yervoy (Bristol Myers Squibb)
4.11.2.3 Orteronel (Millenium Pharmaceuticals)
4.11.3 Phase II development
4.11.3.1 GDC-0980 (Roche)
4.11.3.2 GDC-0068 (Roche)
4.11.3.3 PSMA ADC (Progenics Pharmaceuticals)
4.11.3.4 Galeterone (Tokai Pharmaceuticals)
4.11.3.5 OGX-427 (OncoGenex Pharmaceuticals)
4.11.3.6 ARN-509 (Johnson & Johnson)
4.11.3.7 Abituzumab (Dl7E6) (Merck)
4.11.3.8 Ipilimumab (Yervoy) (Bristol Myers Squibb)
4.11.4 Phase I
4.11.4.1 ASG-5ME (Agensys/Seattle Genetics)
4.11.4.2 EMD-525797 (EMD Serono)
4.11.4.3 MGAH22 (MacroGenics)
4.11.4.4 RG7450 (Roche)
4.11.4.5 BAY2010112 (Bayer Pharmaceuticals)
4.11.4.6 BX-201 (Bellicum Pharmaceuticals)
4.12 The Leading Companies in the Prostate Cancer Drugs Market, 2014
4.12.1 Johnson & Johnson (J&J)
4.12.1.1 Sales and Performance Analysis, 2013
4.12.1.2 Pharmaceutical Segment Sales Analysis, 2013
4.12.1.3 Oncology Drugs Sales and Performance Analysis, 2013
4.12.1.4 Pharmaceutical Segment R&D Performance Analysis, 2013
4.12.1.5 Recent M&A Activity
4.12.1.5.1 Acquisition of Aragon Pharmaceuticals
4.12.2 AstraZeneca
4.12.2.1 Sales and Performance Analysis, 2013
4.12.2.2 Pharmaceutical Segment Sales Analysis by Segment, 2013
4.12.2.3 Oncology Drugs Sales and Performance Analysis, 2013
4.12.2.4 R&D Performance Analysis, 2013
4.12.3 Sanofi
4.12.3.1 Sales and Performance Analysis, 2013
4.12.3.2 Sales and Performance Analysis by Segment, 2012
4.12.3.3 Oncology Sales and Performance Analysis, 2013
4.12.3.4 R&D Performance Analysis, 2013
4.12.3.5 Oncology Pipeline Portfolio
4.12.4 AbbVie
4.12.4.1 Sales and Performance Analysis, 2013
4.12.4.2 R&D Performance Analysis, 2013
4.12.4.3 Oncology Portfolio Pipeline Products, 2013
5. The Prostate Cancer Devices Market 2014-2024
5.1 The Prostate Cancer Devices Market 2013
5.2 The Prostate Cancer Devices Market Forecast, 2014-2024
5.2.1 The Market Shares of Leading Prostate Cancer Devices Submarkets, 2014-2024
5.3 The Brachytherapy Market, 2014-2024
5.4 The Radical Prostatectomy Market 2014-2024
5.4.1 Intuitive Surgical’s da Vinci Surgical System will Drive Market Growth
5.5 The External Beam Radiation Therapy Market, 2014-2024
5.6 The HIFU Market, 2014-2024
5.7 The Cryotherapy Market, 2014-2024
5.8 Leading Companies in the Prostate Cancer Devices Market 2014-2024
5.8.1 Varian Medical Systems
5.8.1.1 Sales and Performance Analysis, 2013
5.8.1.2 Oncology Segment Sales Analysis, 2013
5.8.1.3 Sales Analysis by Region, 2013
5.8.1.4 R&D Performance Analysis, 2013
5.8.1.5 Key Oncology Products, 2013
5.8.1.6 Varian and Siemens Partnership: Shaping the Future of Cancer Care
5.8.2 Elekta
5.8.2.1 Sales and Performance Analysis, 2013
5.8.2.2 Sales and Performance Analysis by Region, 2012
5.8.2.3 Elekta and Philips Establish Research Consortium
5.8.2.4 Product Launch and Development, 2013
5.8.3 Theragenics Corporation (acquired by Juniper)
5.8.3.1 Theragenics Sales Performance Analysis, 2012
5.8.3.2 Theragenics Sales Performance by Operation, 2012
5.8.3.3 Theragenics sales and Performance Analysis by Business Unit, 2012
5.8.3.4 Mergers and Acquisitions
5.8.3.4.1 Juniper’s acquisition of Theragenics
5.8.3.4.2 Acquisition of Needle Tech Products
5.8.3.4.3 Acquisition of Galt Medical
5.8.3.4.4 Acquisition of CP Medical
6. The Leading National Markets 2014-2024
6.1 Regional Breakdown of the Prostate Cancer Therapeutics Market, 2013
6.2 The Prostate Cancer Therapeutics Market: Regional Forecast, 2014-2024
6.2.1 Market Shares Forecasts of Leading National Prostate Cancer Therapeutics
Markets, 2014-2024
6.3 The US Prostate Cancer Therapeutics Market 2014-2024: Largest National Market
6.4 The European Prostate Cancer Therapeutics Market, 2013
6.4.1 The European Prostate Cancer Therapeutics Market, 2014-2024
6.4.1.1 The German Prostate Cancer Therapeutics Market, 2014-2024
6.4.1.2 The French Prostate Cancer Therapeutics Market, 2014-2024
6.4.1.3 The UK Prostate Cancer Therapeutics Market, 2014-2024
6.4.1.4 The Spanish Prostate Cancer Therapeutics Market, 2014-2024
6.4.1.5 The Italian Prostate Cancer Therapeutics Market, 2014-2024
6.5 The Japanese Prostate Cancer Therapeutics Market, 2014-2024
6.6 The Brazilian Prostate Cancer Therapeutics Market, 2014-2024
6.7 The Russian Prostate Cancer Therapeutics Market, 2014-2024
6.8 The Indian Prostate Cancer Therapeutics Market, 2014-2024
6.9 The Chinese Prostate Cancer Therapeutics Market, 2014-2024
6.10 The South Korean Prostate Cancer Therapeutics Market, 2014-2024
6.11 The Mexican Prostate Cancer Therapeutics Market, 2014-2024
6.12 The Rest of the World Prostate Cancer Therapeutics Market, 2014-2024
7. Qualitative Analysis of the Prostate Cancer Therapeutics Market 2014-2024
7.1 SWOT Analysis, 2014-2024
7.2 Strengths
7.2.1 Prostate Cancer is a High Profile Disease
7.2.2 Rapidly Expanding Ageing Population
7.2.3 Targeted Therapies can Command Premium Prices
7.2.4 Strong R&D Pipeline
7.2.5 Successful Launches through Partnerships between Small/Big Pharma Companies
7.2.6 Use of Off-label Drugs is Common
7.3 Weaknesses
7.3.1 Prostate Cancer Drugs are Expensive
7.3.2 R&D Failures in Late-stage Development
7.3.3 Controversy Over the Value of New Prostate Cancer Devices
7.3.4 U.S Medical Excise Tax
7.4 Opportunities
7.4.1 Rising Incidence of cancer
7.4.2 Emerging National Markets will Drive Growth
7.4.3 Stem Cells Offer Promise
7.4.4 Advances in Diagnostic Technologies: CTC as a Biomarker
7.5 Threats
7.5.1 Concerns about Efficacy and Toxicity of Drugs
7.5.2 Who will Pay for the High Cost of Drugs and Devices?
7.5.3 Governments Decreasing Healthcare Spending
7.5.4 Increase in Generic Competition
7.5.5 Increase in the Practice of ‘Active Surveillance’
7.6 Porter’s Five Force Analysis
7.6.1 Rivalry Among Competitors [High]
7.6.2 Threat of New Entrants [High]
7.6.3 Power of Suppliers [Low]
7.6.4 Power of Buyers [High]
7.6.5 Threat of Substitutes [Low]
8. Expert Opinions
8.1 Professor Malcolm Mason, Cancer Research UK’s Prostate Cancer Expert
8.1.1 Factors Affecting the Growth of Prostate Cancer
8.1.2 Prostate Cancer: To Treat or Not to Treat?
8.1.3 Alternatives to PSA Testing
8.1.4 A Common Option for Early Stage Prostate Cancer: Radical Prostatectomy
8.1.5 Large Number of Clinical Trials Studying Prostate Cancer
8.1.6 Combination Therapy: Better Survival Rates
8.1.7 Novel Prostate Cancer Drugs: A Question of Cost
8.2 Interview with Hans Kolam, Chief Financial Officer and Helen Tuvesson, Chief Scientific Officer, Active Biotech
8.2.1 Tasquinimod: Phase III Pre-Chemotherapy Study
8.2.2 Tasquinimod: An Innovative Mode of Prostate Cancer Treatment
8.2.3 Active Biotech/Ipsen: Partnerships are Pivotal for Oncology Drug Development
8.2.4 Tasquinimod: Other Indications in the Pipeline
8.2.5 Competitive Landscape of the Prostate Cancer Drugs Market
8.2.6 The Drivers of Growth in the Prostate Market
8.3 Dr. Estuardo Aguilar-Cordova, Co-founder, CEO and Chairman, Advantagene
8.3.1 ProstAtak’s Mechanism for Prostate Cancer Prevention
8.3.2 ProsAtak’s Market Size
8.3.3 Immunotherapy: The Future for Cancer Treatment
8.3.4 Active Surveillance: A growing Trend
9. Conclusions
9.1 The Prostate Cancer Therapeutics Market, 2014-2024
9.2 The US Will Remain the Largest National Market from 2014 to 2024
9.3 Concluding Remarks
【レポート販売概要】
■ タイトル：世界の前立腺がん治療市場予測：前立腺がん治療薬、前立腺がん治療デバイス■ 英文：The Prostate Cancer Therapeutics Market 2014-2024
Opportunities for Leading Companies
■ 発行日：2014年7月
■ 調査会社：visiongain
■ 商品コード：VISG409047
■ 調査対象地域：グローバル
- 米国のバイオ燃料産業：Biofuel Industry in the United StatesBiofuels are liquid, solid, or gaseous fuels derived from renewable biological sources. Biomass can be burned directly for thermal energy or converted to other high-value energy sources including ethanol, biodiesel, methanol, hydrogen, or methane. Currently, ethanol from corn grain and biodiesel are the only biofuels produced in the United States on an industrial scale. Most of the four billion ga …
- 鉄欠乏性貧血(Iron Deficiency Anemia)：世界の治験レビュー2014年下半期版Iron Deficiency Anemia Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Iron Deficiency Anemia Global Clinical Trials Review, H2, 2014" provides data on the Iron Deficiency Anemia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Iron Deficiency Anemia. It includes an overview of the trial numbers and …
- 世界の航空機異常モニタリングシステム市場（2014-2018）TechNavio's analysts forecast the Global Aircraft Health Monitoring System market to grow at a CAGR of 2.19 percent over the period 2013-2018. One of the key factors contributing to this market growth is the necessity of electronics in aircrafts. The Global Aircraft Health Monitoring System market has also been witnessing the increase in MRO partnerships. However, the complex regulatory requiremen …
- Mobile? Commerce Solutions and Market OpportunitiesMobile commerce is exploding with solutions, applications, and services driven by emerging technologies, use cases, and business models. M-commerce is quite different from traditional e-commerce as the ecosystem and value chain are more dynamic and are evolving in a different manner than e-commerce as a whole. ? This report bundle is the most comprehensive research covering the market for Mobile C …
- 世界のワクチン市場：伝染病、ガン、アレルギー、糖尿病、心血管疾患などThe vaccine market is an established segment and is widely accepted as an indispensable division of the healthcare industry. It is poised to grow rapidly by addressing the following: emerging infectious agents, various types of cancer, allergies, cardiovascular diseases, diabetes, smoke cessation, and neurodegenerative disorders. The global vaccine market is estimated at $32.05 billion in 2013 and …
- 世界のSaaS型企業リソース計画ソフト市場動向（2012-2016）TechNavio's analysts forecast the Global Software-as-a-Service based Enterprise Resource Planning (SaaS-based ERP) Software market to grow at a CAGR of 13.93 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand from SMEs. The market has also been witnessing increased influence from social media and mobile apps. However, data security …
- 世界のモリブデン市場：市場規模、動向、メーカー動向Scope The report presents a thorough study of molybdenum, covering both global and regional markets It aims to give a proper picture of the market, as well as its trends, perspectives and opportunities Comprehensive data showing molybdenum production, consumption, trade statistics and prices are provided (both nationwide and worldwide) Each country’s market overview covers the following: molybdenu …
- 細胞培養用タンパク質表面処理の世界市場2017-2021ABSTRACTAbout Cell Culture Protein Surface Coating Cell culture protein surface coating is a procedure in which the cell culture surfaces are coated with proteins or extracellular matrix (ECM) components to enhance the adhesion and proliferation of the cells during in vitro isolation and cultivation. Proteins that are used in coating cells are collagen, fibronectin, vitronectin, laminin, and osteo …
- 世界の塗料市場2014：主要企業の戦略的分析Complete report $12,700. Individual company assessments $2,450. This thought-provoking report on performance, capabilities, goals and strategies of the major competitors in the worldwide paints and coatings market is designed to provide the industry executives with strategically significant competitor information, analysis, and insight critical to the development and implementation of effect …
- LTCC (低温同時焼成セラミックス)・HTCC (高温同時焼成セラミックス)の世界市場予測（～2024年）‘’The LTCC market and HTCC marketis projected to register a CAGR of 4.5%, in terms of value, between 2019 and 2024.’’ The LTCC market and HTCC market size is estimated to be USD 916 million in 2019 and is projected to reach USD 1.1 billion by 2024, at a CAGR of 4.5% between 2019 and 2024. Co-fired ceramics are used in different industries such as aerospace & defense, automotive, telecommunications …
- 動物用ワクチンの世界市場：家畜用ワクチン、コンパニオン動物用ワクチン、家禽用ワクチン、馬用ワクチン、豚用ワクチンThe report segments the veterinary vaccines market on the basis of products, diseases, technologies, and regions. On basis of products, the veterinary vaccines market is categorized into companion animal vaccines, livestock vaccine, poultry vaccines, porcine vaccines, equine vaccines, aquaculture vaccines, and other animal vaccines. Among these, the companion animal vaccines segment is the fastest …
- レーザー距離計（LDM）の世界市場2016-2020About the Laser Distance Meter Market Laser distance meter (LDM) are used in different industries such as construction and real estate. They have applications like finding out electrical wiring and furniture length in carpentry, interior designing, and carpet flooring. Professional contractors such as solar energy solution providers are widely using them for panel installation and commissioning. T …
- 感圧テープの世界市場2015-2019About Pressure Sensitive Tapes Pressure sensitive tapes are adhesive tapes that stick to a surface when pressure is applied to it, without the need for any solvent, heat, or any other substance. Many variants of these tapes are available in market such as single-sided tape, double-sided tape, adhesive-transfer tape or transfer adhesive, single-coated tape, double-coated tape, carton-sealing tapes, …
- 2014年戦略提言：ヨーロッパの治療薬物モニタリング(TDM)市場This new 291-page report from Venture Planning Group provides a comprehensive analysis of the European therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and sales forecasts by country and market segment for the following assays: Amikacin, Car …
- アジアの睡眠時無呼吸診断装置市場Asia-Pacific Sleep Apnea Diagnostic Systems Market Outlook to 2021 Summary GlobalData’s new report, "Asia-Pacific Sleep Apnea Diagnostic Systems Market Outlook to 2021", provides key market data on the Asia-Pacific Sleep Apnea Diagnostic Systems market. The report provides value, in millions of US dollars, volume (in units) and average price data (in US dollars), within market segments Fixed Polys …
